FTSE MIB
34.571,48 +232,16 (+0,68%) Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
79,85 +0,59 (+0,74%) Bitcoin EUR
58.459,88 +1.569,39 (+2,76%)
Sutro Biopharma, Inc. (STRO)
Dopo ore:
| Chiusura precedente | 4,2800 |
| Aperto | 4,2700 |
| Denaro | 4,3200 x 200 |
| Lettera | 4,3700 x 200 |
| Min-Max giorno | 4,1750 - 4,4900 |
| Intervallo di 52 settimane | 2,0100 - 6,1300 |
| Volume | |
| Media Volume | 997.554 |
| Capitalizzazione | 355,676M |
| Beta (5 anni mensile) | 1,09 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,7800 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,80 |
GlobeNewswireSutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs,
- GlobeNewswire
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate: Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT Locat
- GlobeNewswire
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to a
